Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
145 hedge funds and large institutions have $322M invested in Cymabay Therapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 21 closing their positions.
119% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 21
21% more funds holding
Funds holding: 120 → 145 (+25)
14% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 36
23% less capital invested
Capital invested by funds: $416M → $322M (-$94.1M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
52% less call options, than puts
Call options by funds: $1.9M | Put options by funds: $3.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$6.59M |
| 2 |
Goldman Sachs
New York
|
+$6.44M |
| 3 |
Two Sigma Advisers
New York
|
+$6.11M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.29M |
| 5 |
BlackRock
New York
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$12.6M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$12.4M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.4M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$7.67M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.54M |
CBAY Hedge Fund Activity: Q4 2020 in Review
145 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2020, worth a combined $322M — down 23% from $416M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new CBAY positions and 21 closed out — a net gain of 25 holders — while 41 added to existing stakes and 36 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $6.59M. The largest seller was Invesco, cutting an estimated $12.6M.
- 145 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2020, up from 120 in Q3 2020.
- Funds reported $322M of Cymabay Therapeutics stock for Q4 2020, down 23% quarter-over-quarter.
- 46 funds opened new Cymabay Therapeutics positions in Q4 2020 and 21 closed out, a net change of +25 holders.
- The largest Cymabay Therapeutics buyer in Q4 2020 was Two Sigma Investments, an estimated $6.59M added.
- The largest Cymabay Therapeutics seller in Q4 2020 was Invesco, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2020.